What is Tepezza and How Does it Work?
The Unsafe Drug and Medical Device Team at Anapol Weiss is currently investigating Tepezza. Tepezza is an infusion drug therapy indicated for the treatment of Thyroid Eye Disease (“TED”), including conditions also called Graves’ Eye Disease, Graves’ Ophthalmopathy, or Graves’ Orbitopathy. In January of 2020, Tepezza (also known as Teprotumumab), manufactured by Horizon Pharmaceuticals, Inc. (“Horizon”), was approved by the U.S. Food and Drug Administration (“FDA”). It is the first and only drug to be approved for thyroid eye disease.
Tepezza & Hearing Loss – What we Know So Far
Prior to FDA approval, patients in the clinical trials complained of hearing loss and impairment as well as tinnitus (ringing in the ears) following the usage of Tepezza. During the FDA review process, Horizon acknowledged the potential side effects of hearing loss or damage, but characterized it as only as temporary hearing loss, limited in duration and affecting only 10% of the patients. However, a study published in March of 2021 of the Journal Endocrine Society, reported that 65% of patients who took Tepezza, experienced some level of hearing loss, hearing damage, or tinnitus. Moreover, in February of 2022, an observational study published by the American Journal of Ophthalmology, revealed that in 3 out of 5 patients with Tepezza-related hearing loss, there was persistent subjective hearing-loss at their last follow-up appointments, in stark contrast to Horizon’s claim that the hearing impairment was temporary.
Do You Think You Have a Tepezza Hearing Loss Case?
Speak With Our Legal Team
215-608-9645Tepezza Hearing Loss Lawsuits:
Lawsuits are presently being filed against Horizon inter alia for its failure to disclose this known risk of permanent hearing loss and other hearing impairment injuries from the usage of Tepezza. There are approximately 20 Tepezza lawsuits currently filed in federal court, with 11 pending in the Northern District of Illinois. There is a Motion to Consolidate and Centralize all 11 cases pending in the Northern District of Illinois, with potentially dozens more lawsuits to be filed in the Northern District of Illinois, alone.
Anapol Weiss shareholder Tracy Finken Magnotta is one of the leaders in the Tepezza cases, and was appointed to Plaintiffs’ Executive Committee by the Honorable Thomas M. Durkin for the multi-district litigation In Re: Tepezza Marketing, Sales Practices, and Products Liability Litigation MDL No. 3079.
Mass Torts Practice Areas
Find a Tepezza Lawyer for Your Case:
Our attorneys at Anapol Weiss are here to help. Contact us today for a free consultation to learn more about your right and options.